GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to redu...
Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced the continued advancement of its AI ecosystem – ...
The U.S. Food and Drug Administration issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enable...
Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and c...
- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooli...
-Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, a...
Nanochon, a medical device company developing Chondrograft, a novel patented implant for the treatment of articular cartilage defects of the knee, announ...
In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement ...
Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, announced a multi-program collaboration with a San Diego-based...
Cycle Pharmaceuticals (“Cycle”), a global pharmaceutical company focused on rare diseases, and Forma Life Sciences, Inc. (“Forma”...
NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative t...
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargar...
Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, announced multiple U.S. Food and Drug Adm...
Revvity’s new maternal and fetal biochemistry testing platform Designed for accessibility, simplicity, and flexibility Purpose-built for small...
© 2026 Biopharma Boardroom. All Rights Reserved.
